Vector BioPharma and iBET collaborate to develop high-throughput analytical methods and scalable processes for gene delivery

• Collaboration set to develop and implement high-throughput analytical methods in support of Vector BioPharma’s CMC (chemistry, manufacturing and controls) development
• Project to accelerate the technical development of Vector BioPharma’s gene delivery platform
• Announcement follows Vector BioPharma’s $30 million Series A fundraising in August 2022

 

Basel, Switzerland, 10 January 2023: Vector BioPharma AG (Vector BioPharma), a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery to improve treatments for patients, today announced that it has entered into a strategic, multi-phase collaboration with the Instituto de Biologia Experimental e Tecnológica (iBET), a world-leading research-intensive organization specialized in biotechnology research and bioprocess development. The partnership aims to develop high-throughput quantification methods to advance the technical development of Vector’s gene delivery platform.

 

Vector BioPharma’s gene delivery platform combines high-capacity virus-like particles with exogenous, high-avidity adapter proteins. Utilizing iBET’s expertise in developing integrated bioprocesses and analytical methods for the production, purification and characterization of virus-based pharmaceuticals, the collaboration will be executed in multiple stages. Initially, the collaboration will seek to develop a high-throughput analytical method for full-to-empty capsid ratio quantification from both in-process and final purified samples. Monitoring the full-to-empty capsid ratio, which is a critical quality attribute of virus-based biotherapeutics, is used to determine the purity and safety of such products during the manufacturing process and at the final product stage. Subsequent collaboration stages will focus on the upstream process development for the large-scale manufacturing of Vector BioPharma’s virus-like particles.

 

Lorenz Mayr, Ph.D., CEO at Vector BioPharma, said: “Collaboration with industry-leading R&D institutions and researchers in the biopharmaceutical manufacturing sector is key to accelerating the development of Vector BioPharma’s proprietary gene delivery platform as we look towards large scale and GMP manufacturing. Considering iBET’s track record of prestigious RD&I technology transfer projects with companies across the globe, we are confident in this project to rapidly accelerate the development of our gene delivery platform.”   

 

Micha Häuptle, Ph.D., Head of CMC at Vector BioPharma, said: “We are delighted to enter a collaboration with iBET, a world-class expert in the field of manufacturing process and analytical development for viral vectors. We look forward to leveraging iBET’s experience in the virus-based biopharmaceutical sector, for the development of precise analytical methods and robust manufacturing processes for Vector BioPharma’s virus-like particles designed for precise gene delivery.”

 

Paula Alves, Ph.D., CEO at iBET, said: “iBET is thrilled to partner with such a creative team as Vector BioPharma which, like us, excels at applying cutting-edge technologies from academic research to create innovative viral vectors for gene delivery. Vector BioPharma’s challenges to develop next-generation therapeutics for high-precision gene delivery will motivate our efforts to succeed. This partnership is iBET´s most recent contribution to global health initiatives with its bioprocess development and bioanalytics know-how to bring safe and improved medicines to the clinic.”

 

António Roldão, Ph.D., Coordinator of Late-stage R&D Bioproduction Unit at iBET, said: “It is an honour that Vector Biopharma has appointed iBET to partner in the development of such an innovative and potentially transformative new modality. We are confident that the competences and expertise of iBET in bioprocess and analytics development for gene therapy applications will complement Vector BioPharma’s know-how on viral particles engineering to potentiate its innovative gene delivery platform. Looking forward to a fruitful and exciting collaboration.”

 

For further information please contact:

Vector BioPharma AG

Dr. Nicholas Barbet

E-mail: nik.barbet@vectorbiopharma.com

iBET

Dr. Ana Amaral, Head of External Affairs

E-mail: ana.amaral@ibet.pt

Zyme Communications

Dr. Maria Spyrou

Tel: +44 (0)7707 049 640

E-mail: maria.spyrou@zymecommunications.com

 

To opt-out from receiving press releases from Zyme Communications please e-mail info@zymecommunications.com. To view our privacy policy, please click here.

 

About Vector BioPharma

Vector BioPharma is a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery, to improve treatments for patients. Incorporating cutting-edge platform technologies, from world-class academic research at the University of Zürich, Vector BioPharma uses engineered virus-like particles to achieve cell- and tissue-specific delivery and tunable expression of genes and regulators with unprecedented precision.

Founded in 2021, and headquartered in Basel, Switzerland, Vector BioPharma is built and run by an international team of scientists, engineers and pharmaceutical professionals committed to excellence in science.

To learn more about Vector BioPharma, please visit www.vectorbiopharma.com

Follow Vector BioPharma on Twitter (@VectorBiopharma) and LinkedIn (@Vector BioPharma)

 

About iBET (Instituto de Biologia Experimental e Tecnológica)

Founded in 1989 as a Research and Development (R&D) institution dedicated to building bridges between academia and industry, iBET is today the largest non-profit Portuguese private institution dedicated to biotechnology research. A global reference in the application of biotechnology and bioengineering to health, iBET focuses on the development of bioprocessses for Advanced Therapeutic Medicinal Products (ATMPs), vaccines, antibodies and other innovative therapeutic products.

iBET focuses both on R&D projects as well as research contract services, ensured by around 250 researchers, including more than 100 PhDs plus engineers, lab technicians and over 30 PhD students. Inserted in a dynamic and multidisciplinary academic and business network, iBET aims to transfer the knowledge it creates to companies, helping them to innovate, create value, employment and economic growth.

 

To learn more about iBET, please visit www.ibet.pt

Follow iBET on LinkedIn (@iBETportugal) and Twitter (@ibetportugal) .